NCT00860262
Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
See it on ClinicalTrials.gov ↗858 people
48.1%
51.9%
413 womenmiddle line = equal numbers445 men
- Phase
- PHASE3
- Paid for by
- Boehringer Ingelheim
- Finished
- —
- Health conditions
- Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 58.2 years
- Age 65+
- 27.4%
- Weight (BMI)
- mean 129 participants
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Black / African American 53.7% · White 43% · Asian 2.8% · American Indian / Alaska Native 0.3% · Native Hawaiian / Pacific Islander 0.1%
Women left out
No rules that kept women out were found.
Study titles and rules are shown in their original English.